118 related articles for article (PubMed ID: 30368586)
1. Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms.
Maeda A; Irie K; Ando H; Hasegawa A; Taniguchi H; Kadowaki S; Muro K; Tajika M; Aoki M; Inaguma K; Kajita M; Fujimura A; Fukushima S
Cancer Chemother Pharmacol; 2019 Jan; 83(1):107-113. PubMed ID: 30368586
[TBL] [Abstract][Full Text] [Related]
2. Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers.
Kobayashi K; Sugiyama E; Shinozaki E; Wakatsuki T; Tajima M; Kidokoro H; Aoyama T; Nakano Y; Kawakami K; Hashimoto K; Suenaga M; Ichimura T; Ogura M; Chin K; Nakayama I; Ooki A; Takahari D; Suzuki W; Yokokawa T; Minowa Y; Hiraoka T; Suzuki K; Sato H; Hama T; Yamaguchi K
Cancer Chemother Pharmacol; 2021 Jun; 87(6):767-777. PubMed ID: 33635392
[TBL] [Abstract][Full Text] [Related]
3. Association between ABCG2 and SLCO1B1 polymorphisms and adverse drug reactions to regorafenib: a preliminary study
.
Maeda A; Ando H; Ura T; Komori A; Hasegawa A; Taniguchi H; Kadowaki S; Muro K; Tajika M; Kobara M; Matsuzaki M; Hashimoto N; Maeda M; Kojima Y; Aoki M; Kondo E; Mizutani A; Fujimura A
Int J Clin Pharmacol Ther; 2017 May; 55(5):409-415. PubMed ID: 28157071
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities.
Taguchi D; Inoue M; Fukuda K; Yoshida T; Shimazu K; Fujita K; Okuyama H; Matsuhashi N; Tsuji A; Yoshida K; Miura M; Shibata H
Int J Clin Oncol; 2020 Apr; 25(4):531-540. PubMed ID: 31807967
[TBL] [Abstract][Full Text] [Related]
5. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
Kort A; Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jul; 32(7):2205-16. PubMed ID: 25563977
[TBL] [Abstract][Full Text] [Related]
6. Higher Systemic Exposure to Unbound Active Metabolites of Regorafenib Is Associated With Short Progression-Free Survival in Colorectal Cancer Patients.
Kubota Y; Fujita KI; Takahashi T; Sunakawa Y; Ishida H; Hamada K; Ichikawa W; Tsunoda T; Shimada K; Masuo Y; Kato Y; Sasaki Y
Clin Pharmacol Ther; 2020 Sep; 108(3):586-595. PubMed ID: 32034953
[TBL] [Abstract][Full Text] [Related]
7. Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.
Merćep I; Radman I; Trkulja V; Božina T; Šimičević L; Budimir E; Ganoci L; Božina N
Eur J Clin Pharmacol; 2022 Feb; 78(2):227-236. PubMed ID: 34668025
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib use as a possible cause of intestinal perforation.
Adenis A; Kotecki N; Decanter G; Clisant S; Penel N
Acta Oncol; 2013 Nov; 52(8):1789-90. PubMed ID: 24024697
[No Abstract] [Full Text] [Related]
9. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
Rutkowski P; Stępniak J
Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
[TBL] [Abstract][Full Text] [Related]
10.
Božina T; Ganoci L; Karačić E; Šimičević L; Vrkić-Kirhmajer M; Klarica-Domjanović I; Križ T; Sertić Z; Božina N
Ann Hum Biol; 2022 Dec; 49(7-8):323-331. PubMed ID: 36382878
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors.
Verboom MC; Kloth JSL; Swen JJ; Sleijfer S; Reyners AKL; Steeghs N; Mathijssen RHJ; Gelderblom H; Guchelaar HJ
Pharmacogenomics J; 2019 Oct; 19(5):473-479. PubMed ID: 30713339
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib (Stivarga) and gastrointestinal stromal tumours after treatment failure. Radiological improvement but major adverse effects.
Prescrire Int; 2015 Oct; 24(164):234. PubMed ID: 26594725
[TBL] [Abstract][Full Text] [Related]
13. Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects.
Kim Y; Yoon S; Choi Y; Yoon SH; Cho JY; Jang IJ; Yu KS; Chung JY
Sci Rep; 2019 Dec; 9(1):19410. PubMed ID: 31857620
[TBL] [Abstract][Full Text] [Related]
14. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
Koo DH; Ryu MH; Ryoo BY; Beck MY; Na YS; Shin JG; Lee SS; Kim EY; Kang YK
Cancer Chemother Pharmacol; 2015 Jan; 75(1):173-82. PubMed ID: 25417047
[TBL] [Abstract][Full Text] [Related]
15. Mixed effects of OATP1B1, BCRP and NTCP polymorphisms on the population pharmacokinetics of pravastatin in healthy volunteers.
Lu XF; Zhou Y; Bi KS; Chen XH
Xenobiotica; 2016 Sep; 46(9):841-9. PubMed ID: 26744986
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
Shirley M; Keating GM
Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
[TBL] [Abstract][Full Text] [Related]
17. Regorafenib in gastrointestinal stromal tumors.
Sirohi B; Philip DS; Shrikhande SV
Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib-induced hyperammonemic encephalopathy.
Kuo JC; Parakh S; Yip D
J Clin Pharm Ther; 2014 Aug; 39(4):446-8. PubMed ID: 24707992
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
[TBL] [Abstract][Full Text] [Related]
20. Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin.
Zhang D; Ding Y; Wang X; Xin W; Du W; Chen W; Zhang X; Li P
Eur J Clin Pharmacol; 2020 Jul; 76(7):939-946. PubMed ID: 32361904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]